Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Beta-tubulin isotype alterations linked to docetaxel resistance
September 1st, 2005
Beta-tubulin isotype alterations have been linked to docetaxel resistance in breast tumors. "Docetaxel is one of the most active drugs used to treat breast cancer," scientists in Scotland explained. "The cellular target of docetaxel is the microtubule, specifically the beta-tubulin subunit, that comprises a series of isotypes and that can modulate function." In a recent study, K. Shalli and coauthors at the University of Aberdeen "examined the role of alteration in beta-tubulin isotypes in vitro" and "sequenced the beta-tubulin gene to determine if there were mutations, both of which may represent important mechanisms of acquired resistance to...
Source: Women's Health Weekly (2005-09-01)
|
